Driven both by surging demand and rapid technology advancements, an emerging area of health innovation called “bioconvergence” is driving improvements in human health and sustained interest from investors. This episode will explore these new applications merging engineered technologies with scientific disciplines, including in diagnostics, therapeutics, and elsewhere.
Nobel Laureate Dr. Jim Rothman, Dr. Melanie Mathieu of Prellis Biologics, and Daniel Dornbusch of Excision join host Michael Marks for an in-depth discussion covering advancements in CRISPR technology, the role of AI in drug discovery, the future of personalized medicine, and much more.
TechSurge: Deep Tech Podcast